Today: 20 March 2026
LSEG share price: London Stock Exchange Group stock closes higher as buyback notice lands — what to watch next week
25 January 2026
2 mins read

LSEG share price: London Stock Exchange Group stock closes higher as buyback notice lands — what to watch next week

London, Jan 25, 2026, 08:33 GMT — The market has closed.

  • LSEG shares closed Friday up, edging past a modest drop in the FTSE 100.
  • The company issued a new buyback statement announcing another round of shares to be repurchased and canceled.
  • Investors are eyeing UK rate signals alongside LSEG’s results update due late February.

Shares of London Stock Exchange Group plc (LSEG.L) climbed 0.5% on Friday, closing at 8,768 pence. The FTSE 100 edged down 0.07%, wrapping up a volatile week. The stock kicked off the day at 8,734p and fluctuated between 8,666p and 8,770p, with around 1.25 million shares traded. hl.co.uk

London markets are closed for the weekend, yet LSEG remains at the core of trading, data, and clearing operations, making its stock a potential barometer for risk appetite. As investors flip between “risk-on” and “risk-off” stances, turnover and hedging shift rapidly — and those volume changes hit exchange operators hard.

On Friday, LSEG disclosed it acquired 114,040 shares from Citigroup Global Markets on Jan. 22 under its buyback scheme. The company paid a volume-weighted average price of 8,769.15p per share and announced plans to cancel all shares bought. After this, 508,718,720 shares remain outstanding, excluding treasury stock. investegate.co.uk

Buybacks seem simple on paper: a company spends cash to buy back shares, cutting the share count and possibly boosting earnings per share. But in reality, they often signal confidence or serve as a fallback to support returns when new catalysts dry up.

The upcoming numbers are just around the corner. According to LSEG’s investor-relations calendar, preliminary results for the year ending Dec. 31, 2025, will be released on Feb. 26. Investors are watching closely for updates on subscription growth and cost trends. lseg.com

Macro signals returned to focus following Friday’s UK data. Retail sales volumes climbed 0.4% in December compared to November, Reuters reported, defying expectations for a slight decline. Neil Birrell, chief investment officer at Premier Miton, noted the numbers indicated “the UK consumer is in better shape than expected.” reuters.com

Rates remain the key tool. Bank of England policymaker Megan Greene flagged ongoing concerns about wage growth in 2026 and cautioned against the BoE mirroring the U.S. Federal Reserve’s aggressive rate cuts. “Even more concerning,” she noted, “are the forward indicators for wage growth.” reuters.com

LSEG operates globally as a financial markets infrastructure and data provider, covering Data & Analytics, index and benchmark services through FTSE Russell, and post-trade services like clearing—where it acts as the middleman to ensure trade execution. Its Capital Markets division includes the London Stock Exchange and other trading venues, per its company profile. reuters.com

Support from buybacks and a steady data business isn’t guaranteed. Should volatility drop and trading activity wane, fee revenue from clearing and trading could weaken. That might leave the stock more vulnerable to shifts in valuation and interest rates than to its core fundamentals.

London reopens Monday, with investors eyeing fresh buyback announcements and any shifts in UK rate forecasts. They’ll also be looking for early clues on whether last week’s jitters boost market activity. LSEG’s next big date is its Feb. 26 earnings report.

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Aviva share price sinks after Friday selloff — what investors watch ahead of Monday’s London open
Previous Story

Aviva share price sinks after Friday selloff — what investors watch ahead of Monday’s London open

Lloyds share price dips into the weekend as results loom and Deutsche Bank lifts target
Next Story

Lloyds share price dips into the weekend as results loom and Deutsche Bank lifts target

Go toTop